Detecting illnesses before they take hold

There’s more to J&J than baby powder.

They’ve grown into a huge consumer, pharma, and medical devices company. Now they’re entering some heavyweight collabs to do things like detect Alzheimer’s disease in the earliest possible stages, identify throat cancer with a simple saliva test, treat sleep disorders, and they’ve even working towards a potential HIV vaccine.

cospot jnj

Johnson & Johnson announced more than a dozen new collaborations since January 2018. This is to drive the development of novel solutions to positively impact healthcare and improve the health of people around the globe.

This latest series of deals focuses on leveraging advances in science and technology to address areas of high unmet medical need, including the use of artificial intelligence to detect signs of Alzheimer’s disease years before it becomes apparent; the identification of throat cancers with a simple saliva test; and harnessing a microbiome to treat sleep disorders.

They are also working to eliminate HIV. The start of the new trial involving 2,600 women in southern Africa means that for the first time in more than a decade there are two big HIV vaccine clinical trials taking place at the same time.

The new study is testing a two-vaccine combination developed by Johnson & Johnson in partnership with the US National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation. Their first vaccine, also backed by NIH, began a trial last November.

Johnson & Johnson is just one of the many companies in Zuper’s “Health” superannuation fund option that is doing cool stuff to help make the world a better (and healthier) place.

So if you care about things like curing HIV, finding a treatment for Alzheimer’s, and other health related issues, stay tuned for our launch and keep an eye out for our Zuper Health fund which will allow you to put some of your super into companies doing pioneering work in the health space, like Johnson & Johnson.

Zuper Company Spotlights shine a light on the amazing things the companies in our soon to launch funds do. When we launch we encourage you to read our PDS before switching to work out if Zuper is right for you.

userimage
Eran Thomson

Founder and CCO at Zuper Superannuation. I've beaten cancer, been beaten by Mt. Everest, and like to bust rhymes to the beat.

More
Share this article:
Why are compounding returns so magical?
By Zena
What are compound returns? Only the greatest thing ever, well, maybe after tacos. And hot sauce. Cake is also pretty good, but it’s terrible for my m...
More

All material on this website has been prepared by Zuper Financial Pty Ltd (ABN 32 615 224 890) (Zuper), Zuper is a Corporate Authorised Representative (CAR No.125855) of Instreet Investment Ltd (ABN 44 128 813 016; AFSL 434776). The information contained on this website and in our emails is general in nature and has been prepared without taking into account your financial objectives, situation or needs. Before making a decision in relation to your super you should read the Zuper Super PDS, speak to a licensed financial professional and consider if the information is appropriate to you.

Zuper Super is issued by Diversa Trustees Limited (ABN 49 006 421 638), (AFSL No 235153), as trustee of LESF Super (ABN 13 704 288 646).